BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...IR and corporate communications.Oral delivery company Chiasma Inc. (NASDAQ:CHMA) hired John Doyle as CFO.Oncology and immunology play Tiziana Life Sciences plc...
...Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio Inc. Imago BioSciences Inc. ONL Therapeutics Inc. miRagen Therapeutics Inc. Atea Pharmaceuticals Inc. Chiasma Inc. Tiziana Life Sciences plc Arix...
BioCentury | Jan 5, 2018
Company News

China investment company SARI acquiring majority stake in Nerviano

...company has exclusively out-licensed entrectinib (formerly RXDX-101) to Ignyta Inc. (NASDAQ:RXDX) and milciclib (PHA-848125AC) to Tiziana Life Sciences plc...
...Medical Sciences s.r.l., Nerviano Italy Business: Cancer Jaime De Leon entrectinib milciclib PHA-848125AC Chinese Academy of Sciences Ignyta Inc. Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Roche Anaplastic...
BioCentury | Dec 29, 2017
Company News

China's SARI acquiring Nerviano

...company has exclusively out-licensed entrectinib (formerly RXDX-101) to Ignyta Inc. (NASDAQ:RXDX) and milciclib (PHA-848125AC) to Tiziana Life Sciences plc...
...CRAF (RAF1) and multiple receptor tyrosine kinases. Jaime De Leon entrectinib milciclib PHA-848125AC TZLS-201 Chinese Academy of Sciences Ignyta Inc. Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Roche Anaplastic...
BioCentury | Jun 13, 2017
Company News

Management tracks

...June 20. He was head of business development at GE Healthcare. Oncology and immunology play Tiziana Life Sciences plc...
BioCentury | Apr 27, 2017
Clinical News

Milciclib: Ph I data

...to milciclib from Nerviano under a 2015 deal. Nerviano Medical Sciences s.r.l. , Nerviano, Italy Tiziana Life Sciences plc...
...I data Milestone: Start Phase IIa (5/2017); Phase IIa data (3Q18) Chris Lieu milciclib maleate PHA-848125AC Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Cyclin...
BioCentury | Apr 27, 2017
Clinical News

Milciclib: Ph IIa start

...to milciclib from Nerviano under a 2015 deal. Nerviano Medical Sciences s.r.l. , Nerviano, Italy Tiziana Life Sciences plc...
...IIa start Milestone: Start Phase IIa (5/2017); Phase IIa data (3Q18) Julian Zhu milciclib milciclib maleate PHA-848125AC Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Cyclin...
BioCentury | Apr 21, 2017
Clinical News

Tiziana gains on milciclib cancer data

...CDKs) and neurotrophic tyrosine kinase receptor 1 ( TrkA ; NTRK1). Chris Lieu milciclib maleate Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Cyclin...
BioCentury | Jan 6, 2017
Company News

Novimmune, Tiziana deal

...details. Novimmune S.A. , Plan-les-Ouates, Switzerland Tiziana Life Sciences plc (LSE:TILS), London, U.K. Business: Hepatic, Autoimmune, Inflammation Nora Weintraub NI-1201 Novimmune S.A. Tiziana Life Sciences plc Interleukin-6...
BioCentury | Jan 18, 2016
Financial News

Tiziana Life Sciences completes private placement of convertible notes and warrants

Tiziana Life Sciences plc (LSE: TILS ), London, U.K. Business: Cancer Date completed: 2016-01-13 Type: Private placement of convertible notes and warrants Raised: L709,406 ($1 million) Shares: 472,938 Shares outstanding prior: 92.4 million Investor: Existing...
BioCentury | Dec 14, 2015
Financial News

Tiziana Life Sciences completes private placement of convertible notes and warrants

Tiziana Life Sciences plc (LSE: TILS ), London, U.K. Business: Cancer Date completed: 2015-12-08 Type: Private placement of convertible notes and warrants Raised: L3.8 million ($5.8 million) Shares outstanding prior: 92.4 million Investor: Existing investors...
Items per page:
1 - 10 of 19
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

...IR and corporate communications.Oral delivery company Chiasma Inc. (NASDAQ:CHMA) hired John Doyle as CFO.Oncology and immunology play Tiziana Life Sciences plc...
...Fatty acid synthase BC Staff Dynavax Technologies Corp. Avrobio Inc. Imago BioSciences Inc. ONL Therapeutics Inc. miRagen Therapeutics Inc. Atea Pharmaceuticals Inc. Chiasma Inc. Tiziana Life Sciences plc Arix...
BioCentury | Jan 5, 2018
Company News

China investment company SARI acquiring majority stake in Nerviano

...company has exclusively out-licensed entrectinib (formerly RXDX-101) to Ignyta Inc. (NASDAQ:RXDX) and milciclib (PHA-848125AC) to Tiziana Life Sciences plc...
...Medical Sciences s.r.l., Nerviano Italy Business: Cancer Jaime De Leon entrectinib milciclib PHA-848125AC Chinese Academy of Sciences Ignyta Inc. Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Roche Anaplastic...
BioCentury | Dec 29, 2017
Company News

China's SARI acquiring Nerviano

...company has exclusively out-licensed entrectinib (formerly RXDX-101) to Ignyta Inc. (NASDAQ:RXDX) and milciclib (PHA-848125AC) to Tiziana Life Sciences plc...
...CRAF (RAF1) and multiple receptor tyrosine kinases. Jaime De Leon entrectinib milciclib PHA-848125AC TZLS-201 Chinese Academy of Sciences Ignyta Inc. Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Roche Anaplastic...
BioCentury | Jun 13, 2017
Company News

Management tracks

...June 20. He was head of business development at GE Healthcare. Oncology and immunology play Tiziana Life Sciences plc...
BioCentury | Apr 27, 2017
Clinical News

Milciclib: Ph I data

...to milciclib from Nerviano under a 2015 deal. Nerviano Medical Sciences s.r.l. , Nerviano, Italy Tiziana Life Sciences plc...
...I data Milestone: Start Phase IIa (5/2017); Phase IIa data (3Q18) Chris Lieu milciclib maleate PHA-848125AC Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Cyclin...
BioCentury | Apr 27, 2017
Clinical News

Milciclib: Ph IIa start

...to milciclib from Nerviano under a 2015 deal. Nerviano Medical Sciences s.r.l. , Nerviano, Italy Tiziana Life Sciences plc...
...IIa start Milestone: Start Phase IIa (5/2017); Phase IIa data (3Q18) Julian Zhu milciclib milciclib maleate PHA-848125AC Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Cyclin...
BioCentury | Apr 21, 2017
Clinical News

Tiziana gains on milciclib cancer data

...CDKs) and neurotrophic tyrosine kinase receptor 1 ( TrkA ; NTRK1). Chris Lieu milciclib maleate Nerviano Medical Sciences s.r.l. Tiziana Life Sciences plc Cyclin...
BioCentury | Jan 6, 2017
Company News

Novimmune, Tiziana deal

...details. Novimmune S.A. , Plan-les-Ouates, Switzerland Tiziana Life Sciences plc (LSE:TILS), London, U.K. Business: Hepatic, Autoimmune, Inflammation Nora Weintraub NI-1201 Novimmune S.A. Tiziana Life Sciences plc Interleukin-6...
BioCentury | Jan 18, 2016
Financial News

Tiziana Life Sciences completes private placement of convertible notes and warrants

Tiziana Life Sciences plc (LSE: TILS ), London, U.K. Business: Cancer Date completed: 2016-01-13 Type: Private placement of convertible notes and warrants Raised: L709,406 ($1 million) Shares: 472,938 Shares outstanding prior: 92.4 million Investor: Existing...
BioCentury | Dec 14, 2015
Financial News

Tiziana Life Sciences completes private placement of convertible notes and warrants

Tiziana Life Sciences plc (LSE: TILS ), London, U.K. Business: Cancer Date completed: 2015-12-08 Type: Private placement of convertible notes and warrants Raised: L3.8 million ($5.8 million) Shares outstanding prior: 92.4 million Investor: Existing investors...
Items per page:
1 - 10 of 19